Observational studySupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Prevalence and characteristics of persistent taste and smell dysfunction after immune checkpoint inhibitor therapy for cancer.
Observational study in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06495008 (Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Taste and Smell Dysfunction in Patients More Than Two Years After Start of Immune Checkpoint Inhibitor Therapy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo determine the prevalence and characteristics of persistent dysfunction of taste and smell, and salivary parameters in patients after completion of ICI therapy.
methodsIn this cross-sectional study, dysfunction in patients treated for cancer with ICIs was compared with dysfunction in caregivers. Subjective taste and smell dysfunction and their impact on life were evaluated using validated questionnaires. Objective taste and smell were assessed with taste strips and Sniffin' Sticks, and flow rate and biochemical composition of saliva were measured.
resultsA total of 50 patients and 51 caregivers were included. General characteristics of patients did not differ significantly from those of caregivers. Patients had received a median of 14 ICI cycles. The median time since the last ICI cycle was 3.7 years. Six patients (12%) reported mild subjective taste alterations and two (4%) moderate taste alterations, while two caregivers (4%) reported mild taste alterations. Patients scored lower on the appetite subscale and higher on sodium concentration compared to caregivers (respectively, p = 0.017 and p = 0.027). Objective taste and smell function, (un)stimulated saliva flow rates, and xerostomia did not significantly differ between both groups.
conclusionsThese findings suggest that most patients do not experience persistent taste and smell dysfunction, and salivary changes after ICI treatment. However, a subgroup reports symptoms. As subjective experiences may not correspond with objective findings, clinicians should actively inquire about perceived sensory dysfunction as these can impact QoL. TRIAL REGISTRATION NUMBER: NCT06495008 / 2024-01-02.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.